Summary:

Mthera Pharma’s proprietary technology for a pharmaceutical composition utilizing "Daphne genkwa flower extract"—a core research area of the company—for the prevention and treatment of neurodegenerative diseases has been granted a patent by the European Patent Office (EPO) (Registration No: 3539550). Through this decision, the innovation of our technology has been internationally recognized. We plan to secure strong exclusive rights within the European market and solidify our Intellectual Property (IP) portfolio for global drug development by applying for Unitary Patent (UP) status and completing national phase entries in major countries.

Patent Details:

Title of Invention: Pharmaceutical composition for the prevention or treatment of neurodegenerative diseases comprising Daphne genkwa flower extract or fractions thereof as an active ingredient.

Key Efficacy: Protection of nerve cells and regulation of factors inducing neurodegenerative brain diseases.

Target Region: Europe Unitary Patent (UP) registration & Individual entry procedures for major countries (including the UK) are currently in progress.

Future Plans: Leveraging this European patent registration, we plan to accelerate global licensing-out (L/O) for our pipelines, including MT101, and expand local clinical collaborations.